Effects of Concentration and Temperature on the Stability of Nevirapine in Whole Blood and Serum

Clinical Chemistry

Volumn 50, Issue 1, 2004, Pages 209-211

  Bennetto, Chantelle J ^a   King, Jennifer R ^a   Turner, Michele L ^a   Stringer, Jeffrey S A ^a   Acosta, Edward P ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE;

ARTICLE; BLOOD SAMPLING; CENTRIFUGATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG STABILITY; DRUG STORAGE; HEMOCONCENTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INCUBATION TIME; ROOM TEMPERATURE; TEMPERATURE SENSITIVITY;

ANTI-HIV AGENTS; BLOOD SPECIMEN COLLECTION; DRUG STABILITY; HUMANS; NEVIRAPINE; PLASMA; REVERSE TRANSCRIPTASE INHIBITORS; SERUM;

EID: 1642492771     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.026492     Document Type: Article

References (16)

1. Stringer JSA, Sinkala M, Stout JP, Goldenberg RL, Acosta EP, Chapman V, et al. Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings. J Acquir Immune Defic Syndr 2003;32:506-13.
2. Tribut O, Arvieux C, Michelet C, Chapplain JM, Allain H, Bentue-Ferrer D. Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography. Ther Drug Monit 2002;24:554-62.
3. Dailly E, Thomas L, Kergueris MF, Jolliet P, Bourin M. High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase Inhibitor (nevirapine) after liquid-liquid extraction. J Chromatogr B 2001;758:129-35.
4. Lopez RM, Pou L, Gomez MR, Ruiz I, Monterde J. Simple and rapid determination of nevirapine in human serum by reversed-phase high-performance liquid chromatography. J Chromatogr B 2001;751:371-6.
5. Moyer TP, Temesgen Z, Enger R, Estes L, Charlson J, Oliver L, et al. Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study. Clin Chem 1999;45:1465-76.
6. Hugen PW, Verweij-van Wissen CP, Burger DM, Wuis EW, Koopmans PP, Hekster YA. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B 1999;727:139-49.
7. Van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 2000;14:F77-82.
8. Stringer JS, Sinkala M, Chapman V, Acosta EP, Aldrovandi GM, Mudenda V, et al. Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal singe-dose nevirapine. AIDS 2003;17:1659-65.
9. Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, Hofmyer J, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003;187:725-35.
10. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet 1999;354:795-802.
11. Matheson PB, Abrams EJ, Thomas PA, Hernan MA, Thea DM, Lambert G, et al. The New York City Perinatal HIV Transmission Collaborative Study Group. Efficacy of antenatal zidovudine in reducing perinatal transmission of human immunodeficiency virus type 1. J Infect Dis 1995;172:353-8.
12. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
13. Stringer JS, Rouse DJ, Vermund SH, Goldenberg RL, Sinkala M, Stinnett AA. Cost-effective use of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa. J AIDS 2000;24:69-77.
14. Skordis J, Nattrass N. Paying to waste lives: the affordability of reducing mother-to-child transmission of HIV in South Africa. J Health Econ 2002;21:405-21.
15. Creese A, Floyd K, Alban A, Guinness L. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet 2002;359:1635-43.
16. Marseille E, Kahn JG, Mmiro F, Guay L, Musoke P, Fowler MG, et al. Cost effectiveness of single-dose nevirapine regimen for mother and infant to decrease vertical HIV-1 transmission in sub-Saharan Africa. Ann N Y Acad Sci 2000;918:53-6.